Description of blood pressure changes in patients beginning cyclosporin A therapy

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 17-24

  Charnick, S B ^a   Nedelman, J R ^a   Chang, C T ^a   Hwang, D S ^a   Jin, J ^a   Moore, M A ^a   Wong, R ^a   Meligeni, J ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

Cyclosporine; Hypertension; Mixed effects modeling; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MONITORING; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS;

ADULT; AGE FACTORS; BLOOD PRESSURE; BODY WEIGHT; CYCLOSPORINE; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PSORIASIS;

EID: 0031431607     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00003     Document Type: Article

References (59)

1. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one year follow-up of a multicentre trial. Lancet 1983;ii:986-9.
2. Kahan BD, Van Buren CT, Flechner SM, Payne WD, Boileau M, Kerman RH. Cyclosporine immunosuppression mitigates immunologic risk factors in renal transplantation. Transplant Proc 1983; 15:2469-78.
3. Merlon RM, White DJG, Thiru S, Evans DB, Calne TY. Cyclosporine: five years experience in cadaveric renal transplantation. N Engl J Med 1984;310:148-54.
4. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986;311:699-705.
5. Hardesty RL, Griffith BP, Debski RF, Bahnson HT. Experience with cyclosporine in cardiac transplantation. Transplant Proc 1983;15:2553-8.
6. Griffith BP, Hardesty RL, Deeb GM, Starzl TE, Bahnson HT, Cardiac transplantation with cyclosporine A and prednisone. Ann Surg 1982;196:324-9.
7. Wallwork J, Cory-Pearce R, English TA. Cyclosporine for cardiac transplantation: the United Kingdom trial. Transplant Proc 1983; 15:2559-66.
8. Williams R, Blackburn A, Neuberger J, Calne RY. Long-term use of cyclosporin in liver grafting. Q J Med 1985;57:897-916.
9. Zitelli BJ, Gartner JC, Malatack JJ, Shaw BW, Iwatsuki S, Starzl TE. Hepatic homograft survival in pediatric orthotopic liver transplantation with cyclosporine and steroids. Transplant Proc 1983; 15:2592-6.
10. Barren AJ, Kendra JR, Lucas CF, Joss DV, Joshi R, Pendhark P, Hugh-Jones K. Cyclosporine A as a prophylaxis against graft-versus-host disease in 36 patients. Br Med J 1982;285:162-6.
11. Brown MD, Gupta AK, Ellis CN, Rocher LL, Voorhess JJ. Therapy of dermatologic disease with cyclosporin A. Adv Dermatol 1989;4:3-28.
12. Bonomo L, Caccavo D, Lagana B, Mitterhofer AP. Treatment of severe systemic lupus erythematosus, rheumatoid arthritis, and immune vasculitides with cyclosporin A. Semin Clin Immunol 1991; 2:17-22.
13. Feutren G, von Graffenried B. Pharmacology of cyclosporin A (Sandimmune) and clinical experience in inflammatory bowel diseases. Schweiz Med Wschr 1991;121:748-53.
14. Mueller W, Herrmann B. Cyclosporin A for psoriasis. Correspondence. N Engl J Med 1979;301:555.
15. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986;7:256-9.
16. Bos JD. The pathomechanisms of psoriasis: the skin immune system and cyclosporine. Br J Dermatol 1988;118:141-55.
17. Fry L. Psoriasis. Br J Dermatol 1988;119:445-61.
18. Gottlieb AB. Immunologic mechanisms in psoriasis. J Invest Dermatol 1990;95(suppl):18-9.
19. Streilein JW. Speculations on the immunopathogenesis of psoriasis: T-cell violation of a keratinocyte sphere of influence. J Invest Dermatol 1990;95(suppl):20-1.
20. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990;95(suppl):32-4.
21. Nickoloff BJ, Griffiths CEM. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intraepidermal T-cell activation. J Invest Dermatol 1990;95(suppl): 35-7.
22. Baadsgaard O, Fisher GJ, Voorhees JJ, Cooper KD. Interactions of epidermal cells and T cells in inflammatory skin diseases. J Am Acad Dermatol 23:1312-7.
23. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991;127:871-84.
24. Barker JNWN. The pathophysiology of psoriasis. Lancet 1991; 338:227-30.
25. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992;126:1-9.
26. Griffiths CEM, Voorhees JJ. Immunological mechanisms involved in psoriasis. Springer Semin Immunopathol 1992;13:441-54.
27. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM, Turcotte JG, Voorhees JJ. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6.
28. Brown MD, Gupta AK, Ellis CN, Cooper KD, Fisher GJ, Voorhees JJ. Cyclosporine for the treatment of psoriasis. Transplant Proc 1988;20(supp):26-31.
29. Meinardi MMHM, Bos JD. Cyclosporine maintenance therapy in psoriasis. Transplant Proc 1988;20(supp):41-9.
30. Baker BS, Griffiths CEM, Lambert S, Powles AV, Leonard JN, Valdimarsson H, Fry L. The effects of cyclosporine A on T lymphocyte and dendritic cell subpopulations in psoriasis. Transplant Proc 1988;20(supp):72-7.
31. Griffiths CEM, Voorhees JJ. Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective. J Invest Dermatol 1990;95(supp):53-5.
32. Cooper KD, Voorhees JJ, Fisher GJ, Chan LS, Gupta AK, Baadsgaard O. Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 1990;23:1318-28.
33. Borel JF. Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 1990;122(supp):5-12.
34. Timonen P, Friend D, Abeywickrama K, Laburte C. Von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol 1990;122(supp): 33-9.
35. Feutren G, Friend D, Timonen P, Barnes A, Laburte C. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br J Dermatol 1990;122(supp):85-93.
36. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooker KD, Voorhees JJ. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
37. Lowe NJ. Systemic treatment of severe psoriasis: the role of cyclosporine. N Engl J Med 1991;324:333-4.
38. Wong RL, Winslow CM, Cooker KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993;14:69-74.
39. Mozzanico N, Pigatto PD, Finzi AF. Cyclosporin in psoriasis: pathophysiology and experimental data. Dermatology 1993; 187(supp):3-7.
40. Ippolito F. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Dermatology 1993;187(supp):19-29.
41. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine treated renal transplant recipients is sodium dependent. Am J Med 1988;85:134-8.
42. Schachter M. Cyclosporine A and hypertension. J Hypertension 1988;6:511-6.
43. Sturrock NDC, Lang CC, Struthers AD. Cyclosporine-induced nephrotoxicity and hypertension. Br J Hosp Med 1992;48:483-9.
44. Mouquet C, Benalia H, Carayon A, Bitker MO, Luciani J, Viars P. Is the vasoconstrictive effect of cyclosporine mediated by endothelin in kidney transplantation? Transplant Proc 1994;26(1): 277-8.
45. Iwasaki S, Homma T, Kon V. Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Intl 1994;45:592-7.
46. Fozard JR, Menninger K, Schoeffter P. Cardiovascular effects of cyclosporine A and OG 37-325 after chronic administration to conscious rats: role of endothelin. Transplant Proc 1994;26(5): 3006-9.
47. Pei Y, Chan C, Cattran D, Cardella C, Zaltzman J, Lopez M, Tong J, Schachter R, Maurer J. Sustained vasoconstriction associated with daily cyclosporine dose in heart and lung transplant recipients: potential pathophysiologic role of endothelin. J Lab Clin Med 1995;125:113-9.
48. Textor SC, Burnett JC, Romero JC, Canzanello VJ, Taler SJ, Wiesnder R, Porayko M, Krom R, Gores G, Hay E. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Intl 1995;47:1426-33.
49. Chapman JR, Griffiths D, Harding NG, Morris PJ, Reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet 1985;1:128-30.
50. Flechner SM. Cyclosporin therapy. Transplant Immunol 1984;1: 1-4.
51. Curtis JJ, Dubovsky E, Whelcher JD, Luke RG, Dietheim AG, Jones P. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986;11:477-9.
52. Sturrock NDC, Lang CC, Struthers AD. Acutely cyclosporine reduces urinary water output and increases blood pressure before renal blood flow and renal sodium output are affected [Abstract]. American Association of Pharmaceutical Scientists, 1992.
53. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger BS. Acute effects of intravenous cyclosporine on renal function in healthy volunteers. Transplant Proc 1989;21: 915-7.
54. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplant Proc 1990;22:1110-2.
55. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988;34:461-4.
56. Kovarik JM, Mueller EA, VanBree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-7.
57. Elder CA, Moore M, Chang CT, Jin J, Charnick SB, Nedelman JR, Cohen A, Guzzo C, Lowe N, Simpson K, Karara AH, Meligeni JA. Efficacy and pharmacokinetics of two formulations of cyclosporine A in psoriasis patients. J Clin Pharm 1995;35:865-75.
58. SAS Institute Inc. SAS/STAT Software: Changes and Enhancements, Release 6.07. SAS Technical Report P-229. Cary, North Carolina. SAS Institute, Inc., 1992:287-368.
59. Fletcher A, Bulpritt C. Epidemiology of hypertension in the elderly. J Hypertension 1994;12(supp 6):3-5.